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Abstract
Hepatic fibrosis is a common response to virtually all forms of chronic liver injury independent of the etiologic agent. Despite the rela-
tively large population of patients suffering from hepatic fibrosis and cirrhosis, no efficient and well-tolerated drugs are available for the
treatment of this disorder. The lack of efficient treatment options is at least partly because the underlying cellular mechanisms leading
to hepatic fibrosis are only partly understood. It is thus of pivotal importance to better understand the cellular processes contributing
to the progression of hepatic fibrosis. Interestingly in this perspective, a common feature of fibrotic disease of various organs is the acti-
vation of the coagulation cascade and hepatic fibrosis is also accompanied by a local hypercoagulable state. Activated blood coagula-
tion factors directly target liver cells by activating protease-activated receptors (PAR) thereby inducing a plethora of cellular responses
like (among others) proliferation, migration and extracellular matrix production. Coagulation factor driven PAR activation thus estab-
lishes a potential link between activation of the coagulation cascade and the progression of fibrosis. The current review focuses on blood
coagulation factor Xa and summarizes the variety of cellular functions induced by factor Xa-driven PAR-2 activation and the subsequent
consequences for tissue repair and hepatic fibrosis.
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Hepatic fibrosis results from a sustained wound healing response
to chronic liver injury. Although even acute injury will activate
mechanisms of fibrogenesis, the sustained signals associated
with chronic liver disease caused by infection, drugs, metabolic
disorders or auto-immune disease are required for the develop-
ment of substantial fibrosis. Occasionally, fibrosis may be rapidly
progressive over weeks to months, for example as a result of drug
injury, hepatitis C infection after liver transplantation [1], or hepa-
titis C coinfection with HIV [2], but mostly fibrosis evolves over
decades. Any chronic perturbation of hepatic homeostasis may
elicit signals necessary to stimulate fibrogenesis [3]. The end-
stage of liver fibrosis (cirrhosis), and its complications, i.e. portal
hypertension, liver failure and hepatocellular carcinoma, represent
a major healthcare issue worldwide. Despite the increasing burden
of liver fibrosis and cirrhosis, the therapeutic repertoire for the
treatment of these diseases remains limited, because no efficient
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and well-tolerated drugs are available [4]. The only treatment
option currently available for severe end-stage liver disease is
orthotopic liver transplantation. Therefore, there is a clear imper-
ative to develop novel anti-fibrotic agents to combat these life
threatening conditions.
At the cellular level, hepatic fibrosis is, similar to fibrosis in
other organs such as lung, kidney, heart or skin, considered as an
excessive wound healing response to chronic injury leading to
excessive deposition of extracellular matrix (ECM). The distribu-
tion of fibrotic lesions during disease progression is primarily
determined by the nature of the underlying hepatic injury. Thus,
some fibrotic lesions are primarily periportal due to for instance
chronic viral hepatitis, chronic cholestatic diseases and
haemachromatosis, or they can be primarily centrilobular during
steatohepatitis, and chronic venous outflow obstruction.
Additionally, the fibrotic lesions can be divided into those that
result in porto-portal (e.g. cholestatic liver injuries), porto-central
(e.g. viral hepatitis) or centro-portal bridging (e.g. alcoholic liver
disease). Irrespective of the actual location of the lesions, hepatic
fibrosis is characterized by several key features: (1) the persist-
ence of chronic damage to hepatocytes and/or cholangiocytes,
(2) a complex inflammatory cell infiltrate and (3) activation of 
different types of ECM-producing cells with proliferative and 
synthetic features, finally leading to (4) marked changes in the
quality and quantity of the hepatic ECM that distort the hepatic
architecture and lead to an impairment of organ function [3, 5].
The essential difference between cirrhosis and (developing) fibro-
sis is that during cirrhosis more scar tissue is formed that 
distorts the liver parenchyma.
Activation of the coagulation 
cascade during liver fibrosis: 
a puzzling paradox
A common feature of fibrotic disease of various organs is the
activation of the coagulation cascade [6, 7]. Accordingly, a local
hypercoagulable state also accompanies liver fibrosis. Strikingly,
patients diagnosed with liver fibrosis frequently also present
with systemic coagulation deficiency [8]. These observations
might at first appear as a puzzling paradox. One should realize
however, that several procoagulant factors of the clotting cas-
cade (factors (F)II (prothrombin), VII, IX and X), are synthesized
in the liver by hepatocytes. This tissue specific expression is due to
the positive regulation of their transcription by the liver-specific
transcription factor HNF-4 [9–12]. In addition, these so-called
vitamin K-dependent coagulation factors require post-ribosomal
modification for biological activity. Indeed, they possess a spe-
cific number of glutamic acid residues that function as potential
binding sites for calcium bridges in the NH2-terminal region. The
glutamic acid residues are converted to -carboxyglutamic
acids, and this modification is facilitated by a carboxylase that
requires the fat-soluble vitamin K as cofactor (Fig. 1) [13]. In its
naturally occurring state, vitamin K is in the quinone oxidation
state and must be reduced to the hydroquinone form to become
the active cofactor for the vitamin K-dependent carboxylase. The
enzyme responsible for this reduction is present in the liver [14],
and is known as vitamin K epoxide reductase, because it also
reduces vitamin K epoxide formed during the carboxylation reac-
tion. In severe liver disease, both HNF-4 and vitamin K epoxide
reductase levels (and activity) are reduced as the synthetic
capacity of the liver is lost. Consequently, severe liver disease is
accompanied by acquired coagulation deficiencies. However, the
main anticoagulant proteins (i.e. protein (P)C and PS) are also
synthesized in the liver and also require -carboxylation for
proper anticoagulant activity [13]. Thus, as liver disease pro-
gresses the levels of both pro- and anticoagulant proteins
decrease and the balance between pro- and anticoagulation
becomes precarious. The outcome of severe liver disease with
respect to bleeding and/or thrombosis is thus dependent on this
balance and difficult to predict. In addition to decreased PC and
PS activity, hypercoagulability in liver disease may also be
caused by decreased blood flow, and vasculopathy associated
with chronic inflammation or endothelial dysfunction, which are
all prominent features of liver fibrosis. Finally, increased expres-
sion of tissue factor, the initiator of blood coagulation [15], trig-
gered by fibrosis within the hepatic parenchyma [16] is likely to
play an important role in the hypercoagulable state.
In keeping with the notion that activated coagulation accom-
panies liver fibrosis, morphological studies have shown that
there is a close association between parenchymal remodelling
and obliterative lesions of intrahepatic small portal and hepatic
veins during the progression of chronic liver disease towards
cirrhosis. These obliterative lesions are highly suggestive of
intrahepatic thrombotic events. Indeed, microthrombi are pres-
ent in the microvasculature of mice infected with hepatitis virus
[17, 18] and similar findings were subsequently observed in
patients with cirrhosis [19–21]. In a rat model of liver ischaemia
reperfusion injury, which is an important pathological process
that leads to hepatic damage after circulatory shock and major
hepatic surgery [22–24], microthrombi were formed during
ischaemia which inhibited the restoration of liver blood flow 
[25, 26]. Also, acute and chronic carbon tetrachloride-induced
liver injury stimulates hepatic deposition of fibrin and fibrinogen
within the microcirculation [27].
The potential relevance of hypercoagulablity in liver fibrosis has
been demonstrated by observations that intimal fibrosis (which is
highly suggestive of reorganized thrombosis) was observed in
70% of cirrhotic livers [19, 20]. Based on this observation, the
authors suggested that microthrombi in the vasculature disrupt
blood flow thereby leading to ischaemia and subsequent parenchy-
mal extinction (as characterized by irreversible loss of contiguous
hepatocytes due to hepatocyte apoptosis, collapse of the region
between the central veins and their adjacent portal tract, and the
replacement of hepatocytes by fibrotic lesions [19, 20]).
Subsequently, small areas of parenchymal extinction accumulate
and become confluent resulting in cirrhosis [19, 20, 28].
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An alternative explanation by which microthrombi may con-
tribute to cirrhosis comes from early studies reporting that, once
associated with a thrombus, coagulation FXa retains its enzymatic
activity and induces thrombin generation [29–31]. This is particu-
larly relevant as it has been shown that both FXa and thrombin
directly contribute to the progression of (among others) lung and
kidney remodelling [6]. In keeping with this observation, patients
with a thrombus at the site of vascular injury after percutaneous
transluminal coronary angioplasty have a much higher risk of
restenosis than patients without such a thrombus [32].
Accordingly, the presence of microthrombi is strongly related to
disease severity in hepatic infection [33]. Moreover, thrombotic
risk factors (deficiency of protein C, antithrombin III and 
plasminogen) are associated with the extent of fibrosis in non-
alcoholic fatty liver disease and in chronic hepatitis B or C
[34–36]. Finally, studies using thrombogenic FV Leiden mice
show accelerated hepatic fibrogenesis [37]. Accordingly, the FV
Leiden mutation is associated with an increased risk of fibrosis
during chronic hepatitis C infection (odds ratio of 3.28) [38].
Protease-activated receptors: 
the link between coagulation cascade
activation and liver fibrosis
The quandary as to how coagulation factors influence cellular
responses was elucidated by the identification of a novel family of
G-protein coupled receptors, the protease-activated receptors
(PARs). These seven transmembrane domain receptors are acti-
vated in a unique manner by proteolytic cleavage of their N-terminal
extremity, generating a new tethered ligand that binds to the 
second extracellular loop of the receptor [39, 40]. Activated PARs
subsequently induce transmembrane signalling to G proteins trig-
gering a cascade of downstream events involved in cellular func-
tions implicated in (among others) cell survival, cell migration and
inflammation [6]. To date, four PARs (PAR-1 to -4), with distinct
N-terminal cleavage sites and tethered ligand pharmacology, have
been identified. Strikingly, activated coagulation FVIIa, FXa and
thrombin are able to activate these PARs. Indeed, thrombin sig-
nals through PAR-1, -3 and -4, FVIIa in association with tissue 
factor activates PAR-2, while FXa activates both PAR-1 and PAR-2
[41]. Coagulation factor driven PAR activation thus establishes a
potential link between activation of the coagulation cascade and
the progression of fibrosis. This link might be most relevant for
FXa as this coagulation factor occupies a unique position at the
crossroads between coagulation and signalling. On the one hand,
FXa leads to thrombin generation via its procoagulant properties
after which thrombin induces profibrotic responses via PAR-1
activation. On the other hand, FXa induces fibrotic responses by
PAR-2 dependent signalling in a way which is not reminiscent of
thrombin signalling.
The importance of thrombin-induced PAR-1 activation in liver
fibrosis has been established recently (for review, see [42]); how-
ever, the role of PAR-2 and the cellular consequences of its activa-
tion by coagulation FXa has remained remarkably underexplored
in the context of liver fibrosis. This is mainly because it has long
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Fig. 1 Vitamin K-dependent
protein carboxylation. The
gammacarboxylation of coag-
ulation factors requires the
conversion of reduced vitamin
K1 hydroquinone into vitamin
K1 epoxyde. The K1 epoxyde
is then converted to vitamin
K1 quinone by vitamin K1
epoxyde reductase and then
recycled to vitamin K1 hydro-
quinone by the enzyme vita-
min K reductase. R: phytyl
group.
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been thought that FXa signalling (via PAR-1) was only reminiscent
of thrombin signalling. The expression of the thrombin receptors
PAR-1, -3 and -4 has consequently been investigated in different
settings of liver fibrosis [16, 43–45], whereas the expression of
PAR-2 in the setting of liver fibrosis remains underexplored. This
omission seems important as several lines of evidence point 
to PAR-2 as a key player in the progression of a wide pattern of
pathologies in which coagulation cascade activation plays a cru-
cial role (like among others, tissue remodelling, fibrosis and 
cancer [6]). The variety of cellular functions regulated by FXa and
its role in tissue repair and fibrosis, together with the differential
PAR-2 expression in healthy and fibrotic liver, forms the basis for
the current review on FXa/PAR-2 in liver fibrosis.
Expression and distribution 
of human PAR-2 in normal 
and pathological liver tissue
The liver lobule is formed by parenchymal cells, i.e. hepatocytes,
and non-parenchymal cells. In contrast to hepatocytes that occupy
most of the total liver volume and perform the majority of liver
functions, non-parenchymal liver cells contribute only to a minor
portion of the liver volume, but they make up almost 40% to the
total number of liver cells. These non-parenchymal cells include
cells of the supporting stroma, components of the biliary system
and the sinusoidal compartment. The walls of the hepatic sinusoid
are lined by three different cell types: sinusoidal endothelial cells
(SECs), Kupffer cells (KCs) and hepatic stellate cells (HSCs) which
are located in the space of Disse between the hepatocytes and the
hepatic sinusoids [46].
Ongoing research in our laboratory shows that under normal
conditions PAR-2 is expressed by hepatocytes, KCs, the endothe-
lium of large vessels and by bile duct epithelial cells (personal
observation; Fig. 2). Because of strong PAR-2 staining on hepato-
cytes in healthy liver, we cannot yet discriminate between PAR-2
expression on hepatocytes and/or HSCs. However, in rat studies,
PAR-2 expression was also observed on HSCs physiologically 
[44, 45] suggesting that these cells may express PAR-2 in human
beings as well. Interestingly, PAR-2 expression changes during the
progression of liver fibrosis (Fig. 2D–F). Expression in hepatocytes
remains relatively unchanged, but PAR-2 expression is strongly
increased in proliferating biliary duct epithelium to an extent that
correlates with the severity and/or the duration of liver disease.
PAR-2 is also expressed by the endothelium and vascular smooth
muscle cells of newly formed blood vessels in fibrotic septa, and
by (myo)fibroblasts in fibrotic areas (Fig. 2F), whereas several cells
within the inflammatory infiltrate also show PAR-2 expression.
It is noteworthy that in a rodent model of acute liver injury
induced by LPS administration, PAR-2 expression was also
induced. However, in this inflammatory condition, PAR-2 expression
was predominantly induced on KCs and (although to a lesser
extent) hepatocytes, with discrete expression on endothelium and
bile duct epithelium [47]. This observation emphasizes the differ-
ential cellular responses involved in acute or chronic liver injury.
The differential expression of PAR-2 in healthy and diseased
liver tissue, with up-regulation during the pathogenesis of fibrosis,
is in line with studies showing that PAR-2 contributes to fibrotic
disease. For instance, high expression of pulmonary PAR-2 is
observed in acute and chronic lung injury suggesting that PAR-2
participates in inflammation and fibroproliferation during lung
fibrosis [48]. In renal interstitial fibrosis, the expression of -SM
actin and PAR-2 is correlated [49], whereas PAR-2 expression is
increased in biopsies of patients with IgA nephropathy [50].
FXa signalling on PAR-2 
expressing cells, and the relevance 
for liver fibrosis
Following PAR-2 activation, FXa typically induces phosphoinosi-
tides hydrolysis leading to calcium oscillation. FXa also triggers the
phosphorylation of extracellular-signal related kinase and JNK
pathways, leading to initiation of different transcriptional programs
promoting proliferation, differentiation, migration and ECM deposi-
tion [6], all of obvious relevance in the context of hepatic fibrosis.
It should be kept in mind that FXa signal transduction shows a
degree of cell type specificity, but importantly it seems that FXa-
induced signalling pathways are rather similar in cells derived from
the same lineage (e.g. mesenchymal; for a review, see [6]).
Consequently, one could obtain significant insight on the role of
FXa signalling in liver fibrosis by addressing the role of FXa on cells
with similar characteristics as hepatic fibroblasts, epithelial cells,
KCs and SECs. The next paragraph provides an overview of the
known signalling events provoked by FXa in fibroblasts, epithelial
cells, KCs and SECs, and this overview supports the hypothesis
that FXa is an essential player in the pathogenesis of liver fibrosis.
FXa triggers fibroproliferative 
and pro-inflammatory responses 
in mesenchymal cells via PAR-2 
activation
Activated fibroblasts or myofibroblasts are key mediators of organ
fibrosis. Wound healing in general, and pathological fibrosis in
particular, primarily results from myofibrolast-mediated ECM 
synthesis and deposition. The phenotype of the myofibroblast
population in a diseased tissue therefore influences the extent of
fibrosis. In fibrotic livers, myofibroblasts are considered to derive via
activation and proliferation of resident stellate cells and periportal
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fibroblasts [3]. Recent evidence however suggests that fibroblasts
are more heterogeneous than traditionally thought and additional
mechanisms such as recruitment of bone marrow derived cells
and differentiation of resident epithelial cells are described to con-
tribute to the accumulation of myofibroblasts in fibrotic tissues
[51]. Further understanding of the underlying pathogenic mecha-
nisms involved in the accumulation of scar-forming myofibrob-
lasts might help to stop progressive liver fibrosis, which is cur-
rently not yet possible.
HSCs are without question the most studied fibrogenic cells in
the liver. Located in the space of Disse between the hepatocytes
and the hepatic sinusoids, these cells are indeed major mediators
of the fibrotic process during the wound healing response [52].
The discovery of HSC differentiation into myofibroblasts remains
among the most informative discoveries to date in unlocking the
basis for hepatic fibrogenesis. In normal healthy liver, HSCs show
minimal proliferation and collagen synthesis. In injured liver, HSCs
transform to myofibroblasts and subsequently migrate and accu-
mulate at the site of tissue repair where they synthesize various
ECM components [53–58].
A first insight into the role of PAR-2 in HSC activation came
from the observation that specific PAR-2 agonist peptides (syn-
thetic hexapeptides corresponding to the N-terminus of the teth-
ered ligand) are able to activate HSCs leading to cell proliferation
and increased collagen synthesis in rodents [44, 45]. In keeping
with this observation, FXa promotes similar fibroproliferative
responses in a number of other mesenchymal cells. Indeed, FXa is
mitogenic on embryonic, dermal and lung fibroblasts of different
species, on rat pancreatic stellate cells, on murine myoblasts and
smooth muscle cells of both rodent and human origin, and on
human mesangial cells [41, 59–65]. Moreover, FXa enhances the
production of the cytokines/chemoattractants interleukin (IL)-6, 
IL-8 and MCP-1 in dermal and embryonic fibroblasts and in murine
myoblasts [65, 66]. FXa-induced PAR-2 activation also leads to the
release of PAI-1 and transforming growth factor (TGF)- (a power-
ful profibrotic cytokine) in both human mesangial cells and in
embryonic fibroblasts [50, 65]. Finally, FXa acts as a powerful
chemoattractant for murine embryonic fibroblasts and contributes
to differentiation of these fibroblasts into myofibroblasts [65].
Direct proof for the importance of FXa-dependent PAR-2 
signalling in portal fibroblasts and/or other resident fibroblasts
during hepatic fibrosis has not yet been obtained. However, as
already indicated, PAR-2 is expressed on these cell types in
fibrotic liver tissue (Fig. 2). It is therefore tempting to speculate
that FXa signalling indeed activates hepatic fibroblasts and conse-
quently aggravates fibrosis.
FXa triggers pro-inflammatory responses 
and modulates the survival of epithelial cells 
via PAR-2 activation
The liver contains two relevant epithelial cell types: hepatocytes
and cholangiocytes (epithelial cells of the bile duct). The contribution
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Fig. 2 Immunostaining for PAR-2 in normal and cirrhotic human liver. (A–C) In normal liver, a very intense PAR-2 staining is present in hepatocytes (A,
100), and more weakly in the endothelium of larger vessels (B, **, 400), and in bile duct epithelial cells (B, *). Staining was strong in KCs (C, arrows,
400). (D–F). In fibrotic liver, PAR-2 staining remained strong in hepatocytes in regenerative nodules (D, 40). Staining was strongly increased in the
epithelium of newly formed biliary structures (E, arrows, 100) and in the endothelium and smooth muscle cells of small vascular structures (F, arrows,
400), compared with weaker staining in pre-existing bile ducts (E  F,*).
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of hepatocytes to liver fibrosis is considered to be mainly medi-
ated by paracrine effects of the released inflammatory cytokines
leading to the activation of HSCs and KCs. In addition, however,
apoptotic hepatocytes are ingested by KCs leading to the release
of TGF- and subsequent HSC activation [67, 68]. These activated
HSCs subsequently induce profibrotic responses [3].
Activated cholangiocytes also activate HSCs by the secretion of
pro-inflammatory and chemotactic proteins. In addition, prolifera-
tion of the cholangiocytes also aggravates fibrosis [5].
Interestingly, the fact that PAR-2 mRNA expression is increased in
cholangiocytes of bile duct ligated rats might suggest that PAR-2
activation in these cells would contribute to liver fibrosis [45].
PAR-2 expression in cholangiocytes does however not provide
proof that its activation would contribute to fibrosis, and future
experiments should pursue this hypothesis.
Most likely because the concept of FXa signalling in pathology
emerged only recently, the functional consequences of FXa signalling
in liver epithelium and especially its potential pro-inflammatory
role has never been investigated. However, the effects of FXa-
induced PAR-2 activation, especially with respect to pro-inflammatory
responses, on different epithelial cells have been well described.
For instance, FXa induces the activation of the pro-inflammatory
transcription factor NF-B in HeLa cells (derived from cervix ade-
nocarcinoma) [69], and the inflammatory cytokines such as IL-6,
IL-8, MCP-1 or cyclooxygenase 2, respectively, in endothelial,
mesangial and in epithelial and fibroblastic cell lines [70–72]. In
addition, FXa-induced PAR-2 activation enhances PAI-1 gene induc-
tion and TGF- production in epithelial kidney cells [50]. Next to
inducing inflammation, FXa also modulates cell survival. While
FXa induces PAR-1 dependent apoptosis in a broad range of
epithelial cells [73–75] (which is consistent with thrombin-
induced apoptosis in epithelial cells [76]), FXa-dependent PAR-2
activation in cancer cells with an epithelial origin is generally asso-
ciated with cell proliferation (this has for instance been shown using
colon, cervix, breast, pancreas and skin cancer cells [41, 77–82].
Interestingly, PAR-2 expression is strongly up-regulated on
cholangiocytes in fibrotic liver tissue (Fig. 2) and it is thus tempt-
ing to speculate that PAR-2 activation will lead to cholangiocyte
proliferation thereby aggravating fibrosis.
FXa and PAR-2 signalling in inflammatory cells
KCs are the resident macrophages in the liver. They release a vari-
ety of inflammatory mediators, free radicals, fibrogenic cytokines,
as well as ECM proteinases that alter the normal ECM structure
during early stages of liver injury. As already indicated, KCs play a
critical role in promoting HSC activation [83] and they express
PAR-2 in fibrotic conditions. The relevance of PAR-2 expression
on KCs in the progression of fibrosis might be supported by a
recent study showing that sepsis-induced PAR-2 expression on
KCs is correlated with an inflammatory response. Moreover, PAR-
2 inhibition in this rat model of acute liver injury limits tumour
necrosis factor- production and improves outcome [47].
An overwhelming amount of data indicate that FXa and PAR-2
signalling trigger pro-inflammatory responses in inflammatory
cells. Agonists of PAR-2 modulate neutrophil cytokine secretion,
expression of cell adhesion molecules, rolling and migration [84,
85]. PAR-2 activation also enhances the adhesion of peripheral
blood mononuclear cells to endothelial cells [70]. Furthermore,
PAR-2 activation in the lung induces airway constriction, lung
inflammation and protein-rich pulmonary oedema [86].
Accordingly, PAR-2 deficiency reduces inflammation and mortality
in different mouse models of inflammation [84, 87, 88]. Also, FXa
signalling in leucocytes induces tissue factor expression [89], as
well as IL-1, IL-6, IL-8, MCP-1 and CCR-2 release [66, 90–92].
Interestingly, FXa enhances neutrophil chemoattractant produc-
tion after ischaemia/reperfusion in the rat liver [93]. Taken
together, these observations suggest that the prominent expres-
sion of PAR-2 on KCs is potentially related to, or underlies, the
acute inflammatory response induced by FXa.
FX-induced PAR-2 activation modulates 
endothelial barrier permeability
SECs line the sinusoids and are in constant contact with sinusoidal
blood flow and closely associated with hepatocytes, HSCs and
KCs. Changes in SECs can already be detected before fibrosis
using electron microscopy [94–96]. Whether SECs might drive or
initiate fibrosis, as has been suggested [94, 97], is still a matter of
debate. However, SECs are known to play a crucial role in capillar-
ization of the sinusoids which is a hallmark of liver fibrosis.
Indeed, in the fibrotic milieu, the fenestrae in normal SECs are
markedly decreased in number and size, leading to decreased
porosity of the endothelial barrier [98]. Additionally, a discontinu-
ous basement membrane on the basal side of SECs is replaced by
a continuous basement membrane, accompanied by abundant
collagen fibres that accumulate in the space of Disse.
In vitro experimental evidence indicates that FXa signalling
modifies the endothelial barrier function. Indeed, FXa enhances
endothelial barrier integrity via both PAR-1 and PAR-2 [99] and
FXa might therefore contribute to the decreased porosity of the
endothelium observed during liver fibrosis. Moreover, FXa induces
a proangiogenic phenotype in fibroblasts by stimulating VEGF
expression which subsequent induces tube formation [100], a fea-
ture which is reminiscent of the altered topography of the vascu-
larized fibrotic septa, leading to the establishment of intrahepatic
shunts between afferent (portal vein and hepatic artery) and effer-
ent (hepatic vein) vessels of the liver during fibrosis [101–104]. In
addition, in a variety of endothelial in vitro systems, FXa induces a
wide array of pro-inflammatory responses, thereby contributing to
the formation of a vicious cycle which sustains fibrosis progres-
sion. Indeed, via PAR-2 activation mainly, FXa induces the deposi-
tion of connective tissue growth factor [105], it leads to the acti-
vation of NF-B, and the release of IL-6, IL-8, and MCP-1 
[41, 106, 107], which might contribute to leucocyte recruitment.
Furthermore, FXa induces the expression of E-selectin and the
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adhesion molecules ICAM-1 and VCAM-1 resulting in leucocyte
adhesion [108]. Finally, very recent data show that agonist pep-
tide-driven PAR-2 activation triggers ROS generation by endothe-
lial cells [109]. Indeed, oxidative stress plays an important role in
producing liver damage and initiating hepatic fibrogenesis.
Increased ROS is commonly detected in the liver of patients with
chronic liver disease and in most types of experimental liver fibro-
sis [110, 111]. Therefore, it is tempting to speculate that the
release of ROS following FXa-induced PAR-2 activation in the
endothelium might further enhance the fibrotic response, for
instance, by inducing apoptosis of hepatocytes, amplification of
the inflammatory response as discussed in [110], the production
of profibrotic mediators from KCs or by fibroproliferative
responses of (KC-) activated HSCs [112].
Targeting FXa in animal models 
of liver fibrosis
Proof of concept for a role of FXa-PAR-2 signalling in liver fibro-
sis seems to be derived from rodent models of liver fibrosis in
which different FXa inhibitors were used. Indeed, administration of
the low molecular weight heparins enoxaparin, nadroparin and tin-
zaparin all significantly reduced liver fibrosis in a rat bile duct lig-
ation model [113]. Moreover, dalteparin administration markedly
ameliorated fibrosis in a rat model of carbon tetrachloride induced
hepatic fibrogenesis. Importantly, however, it should be realized
that targeting FXa also reduces downstream thrombin formation.
Consequently, the reduced fibrotic response might not be solely
FXa-PAR-2 dependent but also due to diminished thrombin-
induced PAR-1 signalling as this latter signalling pathway is
known to be profibrogenic as well [42].
Summary and conclusions
Several lines of evidence strongly suggest that coagulation FXa
driven PAR-2 activation might play an important role in the pro-
gression of hepatic fibrosis. First, a local hypercoagulable state
frequently accompanies liver fibrosis. Second, PAR-2 expres-
sion is increased in fibrotic liver tissue compared to healthy tis-
sue. Third, FXa-induced signalling promotes profibrotic
responses, like proliferation, differentiation, migration and ECM
deposition, by fibroblasts, epithelial cells, inflammatory cells
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Fig. 3 Model for the contribution of FXa-PAR-2 signalling in liver fibrosis. Depicted are the different PAR-2 expressing liver cells and their potential con-
tribution to the progression of fibrosis as a functional consequence of FXa-signalling. FXa induces cytokine release in hepatocytes (1), cholangiocytes (2)
and KCs (3), it decreases barrier porosity in SECs (4), and it leads to proliferation, migration, ECM production and differentiation into myofibroblasts of
portal fibroblasts (5) and HSCs (6). Moreover, FXa-induced paracrine activation of portal fibroblast (7) and HSCs (8) also leads to proliferation, migra-
tion, ECM production and differentiation into myofibroblasts.
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and endothelial cells of different origin. Most of these in vitro
studies have however not been performed with specific liver
cells and future studies need to establish the exact fibrotic pro-
gram induced by FXa in stellate cells, hepatocytes, cholangio-
cytes, KCs and SECs. Fourth, FXa targeting limits hepatic fibro-
sis in different rodent models.
Based on these data, we propose that FXa-PAR-2 signalling
contributes to the progression of fibrosis via multiple pathways
(summarized in Fig. 3). (i ) FXa induces pro-inflammatory
responses in hepatocyes, cholangiocytes and KCs; (ii ) It
decreases endothelial barrier porosity; (iii ) FXa leads to proliferation,
migration, ECM production and differentiation into myofibroblasts
of portal fibroblasts and HSCs; (iv ) In a paracrine manner it acti-
vates portal fibroblasts HSCs thereby inducing proliferation,
migration, ECM production and differentiation into myofibroblasts
of these cells.
The pathophysiological significance of these novel findings
needs to be established in the upcoming years however. It is of
great importance to fully understand the contribution of FXa-
driven PAR-2 activation to hepatic fibrosis and to prove or refute
an essential role of this agonist–receptor pair in hepatic fibrosis.
Such studies would pave the way for novel anticoagulant treat-
ment strategies to reduce the progression of fibrosis. In this per-
spective, targeting FXa would be of greatest interest as FXa plays
a dual role in hepatic fibrosis. Through its procoagulant effect it
generates thrombin, the profibrotic effects of which are well
known, and via PAR-2-dependent signalling it induces profibrotic
responses by itself. Although anticoagulant treatment thus seems
to be a very exciting possibility to modify the progression of
hepatic fibrosis, careful monitoring of adverse events (i.e. bleed-
ing complications) will be particularly important in view of the
complex dysregulation of the coagulation system that is known to
accompany advanced liver fibrosis. The advent of novel oral anti-
coagulants with a better safety profile is already a first important
step to bringing the clinical applicability of anticoagulants for
hepatic fibrosis closer to the clinic.
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